Questions
Ipamorelin, answered — the questions people actually ask, kept short and cited.
Plain answers on the GH axis, the CJC-1295 pairing, timing, side effects, and approval status.
What does ipamorelin do for you?
In research, ipamorelin makes the pituitary release a pulse of growth hormone by switching on the ghrelin receptor [1]. Its founding study showed potent GH release in rats and swine without raising cortisol [1]. People in research-use communities report better sleep and recovery, but its one human efficacy trial — for post-surgery bowel recovery — failed [3].
Does ipamorelin increase IGF-1?
Not reliably in short studies. GH is supposed to drive the liver to make IGF-1, but in a 15-day rat bone-growth study ipamorelin raised bone growth with no measurable change in total IGF-1 [4]. In rats given a steroid, ipamorelin combined with it did raise IGF-1 [8]. So the IGF-1 response appears context-dependent, not automatic [4][8].
What does ipamorelin peptide do?
Ipamorelin peptide is a five-amino-acid growth hormone secretagogue: it activates the ghrelin receptor (GHS-R1a) on pituitary cells to trigger a GH pulse [1]. Its signature is selectivity — strong GH release without the cortisol and prolactin spike older GHRPs cause [1]. The GH pulse peaks about 40 minutes after an intravenous dose in humans [2].
Does ipamorelin build muscle?
No controlled human trial shows ipamorelin builds muscle. The muscle rationale rests on GH-axis biology and background work on GH-driven nitrogen retention and protein anabolism [9], plus community reports of recovery. But ipamorelin's only human efficacy trial tested bowel recovery and failed [3], and the strongest rodent data is on bone, not muscle [4].
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) and the first selective growth hormone secretagogue, characterized in 1998 [1]. It releases GH by activating the ghrelin receptor, potently but without raising ACTH or cortisol [1]. It is a research chemical, never approved as a drug, with a single failed Phase 2 human trial [3].
What is ipamorelin peptide?
Ipamorelin peptide is a lab-made chain of five amino acids that mimics the hunger hormone ghrelin at its receptor to make the pituitary release growth hormone [1]. Built by modifying an older peptide, GHRP-1, it was engineered to be selective — GH up, stress hormones flat [1]. Its human half-life is about 2 hours [2].
What are the risks of ipamorelin?
The biggest risk is the unknown: no long-term human safety data exists, and the dominant self-injection route has never been studied in humans [3][2]. Mechanism-based cautions involve cancer (IGF-1 is a growth signal) [1], blood sugar [1], and a class-level heart-toxicity signal seen with a related compound in rats [6]. Research-grade material also has unverified purity [3].
Does ipamorelin reduce belly fat?
No human trial shows ipamorelin reduces belly fat. The closest data is indirect: a 2024 ferret study found intraperitoneal ipamorelin (1-3 mg/kg) cut chemotherapy-induced weight loss by about 24%, a peripheral effect on weight, not fat-targeting [5]. Community reports of a slow leaning-out are anecdotal and confounded by diet and training [5].
What are the downsides of ipamorelin?
The honest downside is weak evidence: the one human efficacy trial missed its endpoint (25.3 vs 32.6 hours, p=0.15) [3]. Commonly reported effects include facial flushing, hunger, mild water retention, and injection-site irritation — all anecdotal [3]. Long-term human safety is uncharacterized, and a related ghrelin-receptor drug showed heart-muscle damage in rats [6].
Why is ipamorelin being discontinued?
Ipamorelin was never a marketed drug to discontinue — its clinical development simply stopped after the Phase 2 ileus trial missed its primary endpoint in 2014 (25.3 vs 32.6 hours, p=0.15) [3]. More recently, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list, tightening compounding-pharmacy access [3].
What does CJC-1295 and ipamorelin do?
Together, they push the GH axis through two doors. Ipamorelin pulses GH via the ghrelin receptor [1]; CJC-1295 is a long-acting GHRH analog that, alone, produced 2- to 10-fold GH increases for 6+ days and sustained IGF-1 elevation in healthy adults [10]. The pairing is mechanistically complementary but has never been tested as a combination in any trial [10][3].
How does CJC-1295 ipamorelin work?
The two hit different receptors. Ipamorelin activates the ghrelin receptor (GHS-R1a) to fire a GH pulse [1]; CJC-1295 activates the GHRH receptor for a steadier signal [10]. Pulsatile GH persists even under continuous GHRH-analog stimulation [11], which is the rationale for combining a pulsing GHRP with a sustained GHRH analog [10]. The combination itself is untested in trials [3].
How much CJC-1295 ipamorelin should I take?
There is no research-validated dose, and this site gives none. No human trial has tested the CJC-1295/ipamorelin combination at any dose for any outcome [3][10]. The single-agent record shows ipamorelin's human doses were intravenous in research settings [2] and CJC-1295's effects came from defined subcutaneous study doses of that drug alone [10]. Community 'stack' amounts are anecdotal [3].
Does CJC-1295 ipamorelin work?
The combination has no controlled-trial evidence either way [3]. Single-agent CJC-1295 demonstrably raised GH 2- to 10-fold and sustained IGF-1 in healthy adults [10], and ipamorelin demonstrably pulses GH [1] — but ipamorelin's one human efficacy trial failed [3], and the pairing's popularity rests on mechanism and anecdote, not combination outcome data [10][3].
How to reconstitute CJC-1295 ipamorelin 5mg?
Research-supply sources describe ipamorelin as a lyophilized (freeze-dried) powder reconstituted with bacteriostatic water for lab handling, then kept refrigerated because peptides degrade with heat and freeze-thaw [2]. This is a general handling note, not a preparation or dosing instruction — and no validated human CJC-1295/ipamorelin regimen exists to prepare toward [3].
How long does ipamorelin stay in your system?
Not long. The human pharmacokinetic study reported a terminal half-life of about 2 hours, with the GH pulse peaking around 40 minutes after an intravenous dose [2]. Clearance was 0.078 L/h/kg [2]. As a short-acting peptide, ipamorelin is eliminated within hours, and the GH effect it triggers is a brief spike rather than a sustained level [2].
Does ipamorelin make you hungry?
It can, by mechanism. Ipamorelin works through the ghrelin receptor — the same receptor the body's hunger hormone uses — and ghrelin-receptor agonists activate appetite circuits [1]. Some research-use community members report increased hunger after injecting, described as milder than with GHRP-6 [1]. This reflects the receptor class, not a dose-verified clinical finding [1].
Will I gain weight on ipamorelin?
There is no human trial answering this. Mechanistically, the ghrelin-receptor pathway can raise appetite, which could increase intake [1]. In animals, ipamorelin influenced body composition and, in ferrets, blunted chemotherapy-driven weight loss [5]. Its one human trial (in surgery patients) was not a body-weight study and failed its bowel-recovery endpoint [3]. Any weight effect in research use is unverified.
Does ipamorelin increase appetite?
By mechanism, yes — it is a ghrelin-receptor agonist, and that receptor sits on the brain's appetite circuitry, so increased appetite is a class-level effect [1]. Background GH-axis work also covers nitrogen retention and anabolism that some attach to appetite and protein intake [9]. Community reports note a post-injection hunger uptick, milder than older GHRPs but real for some [1].
How long does it take for ipamorelin to work?
On the GH pulse, fast: in humans the GH response peaks about 40 minutes after an intravenous dose, and the half-life is roughly 2 hours [2]. On reported subjective effects like sleep, research-use community accounts describe noticing changes within one to two weeks — but that is anecdote, not a measured clinical timeline [2].
Does ipamorelin cause water retention?
Some users report mild water retention or puffiness in the first few weeks, described as milder than older GHRP compounds and easing with use — this is anecdotal, not a clinical finding [3]. Mechanistically, GH excess is associated with sodium and water retention, which is part of why fluid-overload conditions are flagged as a caution [3].
Where to inject CJC-1295 ipamorelin?
This site gives no injection instructions. In research, ipamorelin's human dosing was intravenous, while rodent and community use favored the subcutaneous route [2]. CJC-1295's human study doses were subcutaneous [10]. Because there is no approved or validated human CJC-1295/ipamorelin protocol, any administration site is outside any approved use and not something this digest advises on [3].